Skip to main content

Advertisement

Fig. 2 | Cancer Communications

Fig. 2

From: Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)

Fig. 2

Taxane subscale scores for patients with HER2-negative MBC in the EG and PG arms. a Taxane subscale scores for the EG and PG arms; b taxane subscale scores for patients treated with less than 13 cycles or over 13 cycles of the EG or PG regimen; c neuropathy-specific subset scores for the EG and PG arms; d neuropathy-specific subset scores for patients treated with less than 13 cycles or over 13 cycles of the EG or PG regimen. All data are presented as mean values, with bars indicate standard deviation

Back to article page